ONC-783

OncoC4, Inc. · Phase 1 active Small molecule

At a glance

Generic name	ONC-783
Also known as	Bispecific antibody against CD24 and CD3
Sponsor	OncoC4, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ONC-783 CI brief — competitive landscape report
ONC-783 updates RSS · CI watch RSS
OncoC4, Inc. portfolio CI